Latest immunotherapy Stories
ImmunoSelect-R Combines Industry-Leading Accuracy of PGDx's CancerXome(TM) Whole Exome Analysis and Its Predictive Bioinformatics to Guide Selection of Tumor Antigen Therapeutic Targets and Stratify
Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif.
SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody(TM) therapeutics for the treatment of cancer, today announced that Sean McCarthy,
SUNNYVALE, Calif., May 28, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
Updated Survival Data and New Report from Prospective Cohort Suggest Benefits of Sequencing Proleukin Before Targeted Therapies CHICAGO, May 28, 2015 /PRNewswire/ -- Prometheus
Data Demonstrates Extension of Survival of Metastatic Melanoma Patients Treated with Proleukin Followed by Immune Checkpoint Blockade of the Programmed Death (PD-1/PD-L1) Pathway CHICAGO,
NORTH BRUNSWICK, N.J., May 28, 2015 /PRNewswire/ -- PDS Biotechnology Corp.
A new study suggests that having cytoreductive surgery can make immunotherapy more effective for patients with advanced mesothelioma. Raleigh, NC (PRWEB) May
Plasma Cell Disorders, Epidemiology Studies Also Play a Prominent Role NEW YORK, May 26, 2015 /PRNewswire-USNewswire/ -- NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer
Talimogene Laherparepvec First Oncolytic Immunotherapy to Demonstrate Therapeutic Benefit for Patients With Advanced Melanoma THOUSAND OAKS, Calif., May 26, 2015 /PRNewswire/ --
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.